News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Quantinno Capital Management LP significantly increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 374.7% in the first quarter, bringing its total holdings to 137,479 shares valued at $2.19 million. Institutional investors now own 48.06% of FLGT, while company insiders hold 36.18%, with recent …
Sharemaestro market context Price below Trend Line 52 weeks -6.9% · Next-week setup negative 12.1%Tenet Healthcare (THC) Director Tammy Romo sold 7,422 shares on August 7, 2026, for approximately $1.95 million, reducing her total holdings to 28,284 shares. This transaction is part of a trend of 21 insider sells and zero buys over the past year, suggesting a …
Atossa Therapeutics (NASDAQ:ATOS) reported a Q2 2026 net loss of $8.5M but holds $26.1M in cash. The company secured $4.5M upfront in a direct offering, with potential for up to $16.5M, and is advancing its (Z)-endoxifen program through four Phase 2 trials, expecting data …
Tammy Romo, a director at Tenet Healthcare Corp. (NASDAQ:THC), sold approximately $1.95 million worth of common stock in two transactions earlier this month, involving 7,422 shares at prices between $260.83 and $264.15. These sales occurred as Tenet shares approached their 52-week high, following a …
Tenet Healthcare Director Tammy Romo sold 2,500 shares of company stock for over $652,000, reducing her position by 8.12%. This follows a previous sale of 4,922 shares. The stock price closed at $260.33, near its 52-week high, after the company reported strong quarterly earnings …
SOPHiA GENETICS CTO Abhimanyu Verma sold 5,000 shares of the company's stock for $38,000, reducing his total holdings to 182,171 shares. This sale, executed under a Rule 10b5-1 trading plan, follows several other recent insider transactions. Despite the stock trading near its 12-month high, …
Tenet Healthcare Corporation (NYSE:THC) has quietly become one of the strongest-performing healthcare stocks in the market, surging more than 270% over the past five years. That rally reflects a business that has changed significantly: Tenet (NYSE:THC) has expanded its ambulatory surgery platform, increased its …
Levi & Korsinsky is investigating Myriad Genetics (MYGN) for potential securities law violations after the company reported lower-than-expected Q2 2026 revenue, cut its full-year revenue guidance, and suspended adjusted EBITDA guidance. The investigation focuses on whether Myriad Genetics made materially false or misleading statements …
Atossa Therapeutics Inc has reported its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides a brief overview of the company's financial results. Access to the full report is available through a subscription to TradingView.
This article analyzes Fulgent Genetics Inc. (NASDAQ: FLGT), highlighting a near-term strong sentiment despite persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 98.2:1 risk-reward setup, targeting a 28.2% gain versus 0.3% risk. The article details three AI-generated trading …
Mizuho has increased its target price for Tenet Healthcare Corp (THC.N) to $290, up from the previous $250. This adjustment reflects an updated outlook from the analyst firm regarding the healthcare company's valuation. The news was reported by Reuters.
This article identifies three promising penny stocks—Myriad Genetics (MYGN), Claros Mortgage Trust (CMTG), and Nextdoor Holdings (NXDR)—that exhibit strong financial health despite current challenges. Myriad Genetics is expanding its market reach through strategic partnerships, Claros Mortgage Trust has a solid cash runway despite unprofitability, …
Tenet Healthcare Corporation (THC) shows a promising 7.49% upside potential, with its stock currently trading at $262.13. The company, a diversified healthcare services provider with a market capitalization of $21.11 billion, exhibits strong operational metrics including 6.80% revenue growth and a 37.34% return on …
Sei Investments Co. has acquired 357,888 shares of SOPHiA GENETICS SA (NASDAQ:SOPH) for approximately $1.77 million, giving it a 0.52% stake in the company. Despite this institutional investment, SOPHiA GENETICS remains unprofitable, reporting a quarterly loss of $0.26 per share, worse than estimates, although …
Dimensional Fund Advisors LP significantly reduced its stake in Fulgent Genetics (NASDAQ:FLGT) by 24.4% in the first quarter, selling over 217,000 shares. This comes as Fulgent Genetics reported a quarterly loss and revenue below analyst expectations, contributing to a "Hold" consensus rating among analysts. …
Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Myriad Genetics, Inc. (NASDAQ: MYGN) for potential securities law violations. This investigation follows Myriad's Q2 2026 financial results, which showed an 11% year-over-year revenue drop, reduced full-year guidance, and suspended EBITDA guidance, causing …
Argus has increased its rating for Tenet Healthcare Corporation (THC) to a BUY as of July 29, 2026. Tenet Healthcare, a Dallas-based healthcare services organization, operates acute and specialty hospitals and numerous ambulatory surgery centers across the US. The current price for THC is …
Director Roy Blunt sold 600 shares of Tenet Healthcare Corp (THC) for approximately $157,608 on August 5, 2026. This sale contributes to a trend of 20 insider sells and zero buys at the company over the past year. Despite attractive operational metrics, GuruFocus's GF …
Wall Street Zen has downgraded Myriad Genetics (NASDAQ:MYGN) to a "Sell" rating from "Hold," citing the company's recent earnings miss and declining revenue. The stock opened significantly below its moving averages, and the analyst consensus for Myriad Genetics is now "Reduce" with an average …
Wall Street Zen has downgraded Fulgent Genetics (NASDAQ:FLGT) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "hold" with a $27.50 price target. This downgrade follows Fulgent's recent quarterly earnings report, which missed analyst expectations for both EPS and …
Tenet Healthcare director Roy Blunt sold 600 shares of the company's common stock for $157,608 on August 5, 2026. This transaction occurred as the stock trades near its 52-week high, following strong Q2 2026 results that surpassed analyst expectations and led to raised full-year …
This page from TradingView provides financial information for Fulgent Genetics, Inc. (MUN:7F0), specifically focusing on its forward price-to-sales ratio. The content appears to be a stub or a placeholder, as no specific values or detailed data regarding the price-to-sales metric are visible.
Atossa Therapeutics reported a net loss of $8.5 million for Q2 2026, slightly up from the prior year, with operating expenses reaching $8.7 million. The company's cash and cash equivalents stood at $26.1 million and it completed a registered direct offering for $4.5 million …
Atossa Therapeutics, Inc. reported a net loss of $(8.49M) and diluted EPS of $(0.95) for Q2 2026, slightly worse than Q2 2025's net loss but with improved EPS. The company holds $26.1M in cash and cash equivalents but expressed substantial doubt about its ability …
This article presents the slide deck published by Fulgent Genetics, Inc. in conjunction with their Q2 2026 earnings call. The content is provided by Seeking Alpha's transcripts team, which publishes numerous quarterly earnings calls. The aim is to share transcript-related developments with readers.
Prenetics Global Limited (PRE) has detailed a $1 billion growth financing arrangement for its IM8 business with GC Customer Value Arranger, LLC. This agreement allows investors to fund up to $1 billion for IM8's sales and marketing efforts through August 11, 2028. In return, …
Xenetic Biosciences reported its Q2 2026 financial results, showing approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company ended the quarter with $6.5 million in cash and highlighted expanded translational research and collaborations for its DNase platform. Business …
Xenetic Biosciences reported its Q2 2026 financial results, highlighting approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company announced that its collaboration partner, PeriNess Ltd., received Israeli regulatory approvals to conduct an exploratory study of DNase I in …
Xenetic Biosciences announced its second-quarter 2026 financial results, emphasizing continued progress with its proprietary DNase platform. The company reported a 12% increase in royalty revenue due to a sublicense agreement with Takeda Pharmaceuticals, while R&D expenses decreased and G&A expenses rose due to legal …
Search by ticker symbol or company name and select a result to open its chart.